MedPath

Jilin Province Xidian Pharmaceutical SciTech Development Co.,Ltd

Ownership
-
Established
1990-03-21
Employees
269
Market Cap
-
Website
http://www.xidianyy.com
Introduction

The company is a technology-based pharmaceutical enterprise focusing on R&D, production and sales of chemical raw materials and formulations. It is one of the first pharmaceutical companies in Jilin Province to pass the “High-tech Enterprise” certification in 2008. It has also been successively rated as a “National High-tech Enterprise” and a “National Torch Program Key High-tech Enterprise”. After more than 30 years of differentiated development, the company has formed a product system with anti-anemia drugs, drugs for treating mental disorders, and raw materials as the core, and auxiliary drugs for cardiovascular diseases and drugs for anti-tumor treatment. The company is mainly engaged in R&D, production and sales of chemical raw materials and formulations. The company's main products include compound ferrous sulfate folic acid tablets, risperidone tablets, escitalopram oxalate tablets, rexianthin capsules, ferrous fumarate, ferrous sulfate, and reflavin.

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

52

NMPA:52

Drug Approvals

Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution

Product Name
氨溴特罗口服溶液
Approval Number
国药准字H20253429
Approval Date
Feb 20, 2025
NMPA

Risperidone Orally Disintegrating Tablets

Product Name
可同
Approval Number
国药准字H20247236
Approval Date
Sep 30, 2024
NMPA

Risperidone Orally Disintegrating Tablets

Product Name
可同
Approval Number
国药准字H20247235
Approval Date
Sep 30, 2024
NMPA

Rivastigmine Bitartrate Oral Solution

Product Name
重酒石酸利斯的明口服溶液
Approval Number
国药准字H20244273
Approval Date
Jun 28, 2024
NMPA

Roxatidine Acetate Hydrochloride for Injection

Product Name
注射用盐酸罗沙替丁醋酸酯
Approval Number
国药准字H20234148
Approval Date
Sep 12, 2023
NMPA

Esmolol Hydrochloride Injection

Product Name
盐酸艾司洛尔注射液
Approval Number
国药准字H20233872
Approval Date
Jun 30, 2023
NMPA

Ozagrel

Product Name
奥扎格雷
Approval Number
国药准字H20041259
Approval Date
Sep 3, 2021
NMPA

Thymopentin

Product Name
胸腺五肽
Approval Number
国药准字H20054343
Approval Date
Dec 10, 2020
NMPA

Soldium Ozagrel for Injection

Product Name
注射用奥扎格雷钠
Approval Number
国药准字H20041261
Approval Date
Sep 11, 2020
NMPA

Soldium Ozagrel for Injection

Product Name
注射用奥扎格雷钠
Approval Number
国药准字H20041260
Approval Date
Sep 11, 2020
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.